July 18, 2014
1 min read
Save

Eylea shows sustained improvements in BCVA vs. laser photocoagulation

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Data from the phase 3 VIVID-DME trial indicate that aflibercept injection provided sustained improvements in best corrected visual acuity from baseline at 2 years compared with laser photocoagulation in patients with diabetic macular edema.

Patients in the VIVID-DME trial were randomly assigned to either aflibercept (Eylea, Regeneron) 2 mg monthly, aflibercept 2 mg every 2 months or the comparator treatment of laser photocoagulation.

In patients who received aflibercept 2 mg monthly, 2-year data indicated a mean change in BCVA from baseline of 11.4 letters (10.5 letters at 52 weeks, P < .0001 vs. laser), according to a company press release.

Patients assigned to aflibercept 2 mg every 2 months had a mean change in BCVA from baseline of 9.4 letters (10.7 letters at 52 weeks, P < .0001 vs. laser).

The most common adverse events included conjunctival hemorrhage, cataract and increased IOP, according to the release.

Full 2-year data from the VIVID-DME trial will be presented at an upcoming scientific conference, according to the release.